RxDoctor Payments Data

Peggy Harris, APRN

Family · Madisonville, KYNPI 1992173330

Payments from drug & device makers

$1,064in general payments, 2019–2025

Across 60 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$462
  • Axsome Therapeutics, Inc.$161
  • Novo Nordisk$157
  • Amgen$67
  • Edwards Lifesciences$45
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$42
  • plus $131 from 6 others

What the payments were for

  • Food & beverage$1,064100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,064 in reported general payments places this provider in the 65th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$68,056
Medicare patients
212
Services billed
2,522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide93$91,465
EliquisApixaban69$59,800
JardianceEmpagliflozin51$37,111
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$23,977
JanuviaSitagliptin Phosphate12$19,349
XareltoRivaroxaban26$18,634
TradjentaLinagliptin25$17,753
LinzessLinaclotide27$15,238
Repatha SureclickEvolocumab18$13,710
MounjaroTirzepatide12$12,368
MovantikNaloxegol Oxalate13$11,824
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$8,364
Emgality PenGalcanezumab-Gnlm12$8,143
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$7,947
Praluent PenAlirocumab12$5,989

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$157$91,46593 claims
GSKTrelegy Ellipta, Anoro Ellipta$13$29,51351 claims
AbbVieLinzess$462$15,23827 claims
Lilly USA, LLCMounjaro$15$12,36812 claims
AstraZenecaSymbicort$15$4,83021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,374 family providers in Kentucky.

Other family in Madisonville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →